Trial Profile
Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 01 Dec 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 27 Sep 2021 Status changed from recruiting to discontinued.(Reason the study was stopped due to nsufficient accrual ).
- 17 Apr 2019 Status changed from not yet recruiting to recruiting.
- 26 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 Mar 2019.